Biotech

Johnson & Johnson today confirmed reports it is engaged in initial conversations with Actelion Pharmaceuticals “regarding a potential transaction.”

Johnson & Johnson (NYSE:JNJ) today confirmed reports it is engaged in initial conversations with Actelion Pharmaceuticals “regarding a potential transaction.”
According to the press release,

“There can be no assurance any transaction will result from these discussions. Johnson & Johnson does not intend to make any additional comments regarding these discussions unless and until it is appropriate to do so, or a formal agreement has been reached.”

Read the full press release here.

Featured

MARKETS

Markets
TSX22087.57+13.22
TSXV877.82+6.14
DOW34549.71-257.75
S&P 5004494.80-16.81
NASD14122.02+13.20
ASX7341.10+62.60

COMMODITIES

Commodities
Gold1929.54+10.06
Silver24.91+0.17
Copper4.75+0.05
Palladium2525.50+17.50
Platinum1016.00-5.00
Oil114.48+5.21
Heating Oil3.78+0.18
Natural Gas5.26+0.07

DOWNLOAD FREE REPORTS

×